Gastric Ulcer (Helicobacter pylori)

Overview

Plain-Language Overview

Gastric ulcer caused by Helicobacter pylori is a condition where painful sores develop in the lining of the stomach. This happens because the protective layer of the stomach is damaged, allowing acid to irritate the tissue underneath. The main body system involved is the digestive system, specifically the stomach. People with this condition often experience abdominal pain, especially when the stomach is empty. Other symptoms can include nausea, bloating, and sometimes vomiting. If untreated, these ulcers can lead to serious problems like bleeding or perforation. The infection with the bacterium Helicobacter pylori is the most common cause of these ulcers.

Clinical Definition

Gastric ulcer (Helicobacter pylori) is a type of peptic ulcer characterized by a mucosal defect in the stomach wall that extends through the muscularis mucosae. The core pathology involves disruption of the gastric mucosal barrier, leading to acid-mediated injury. The primary cause is chronic infection with the gram-negative bacterium Helicobacter pylori, which induces inflammation and impairs mucosal defenses. This infection increases gastric acid secretion and decreases bicarbonate production, promoting ulcer formation. Clinically, it presents with epigastric pain, often described as burning or gnawing, and may be associated with dyspepsia. Complications include bleeding, perforation, and increased risk of gastric adenocarcinoma. Diagnosis and management focus on eradication of the infection and acid suppression.

Inciting Event

Colonization of the gastric mucosa by Helicobacter pylori initiates chronic gastritis and ulcer formation.
NSAID ingestion triggers mucosal injury by inhibiting cyclooxygenase enzymes.
Acute stress events such as severe illness or trauma can precipitate ulcer formation in susceptible individuals.

Latency Period

Months to years of chronic H. pylori infection typically precede ulcer development.
NSAID-induced ulcers can develop within days to weeks of drug exposure.
Stress-related ulcers may appear within hours to days after the inciting event.

Diagnostic Delay

Nonspecific dyspeptic symptoms often lead to delayed recognition of gastric ulcers.
Misattribution of symptoms to functional dyspepsia or gastritis delays diagnosis.
Lack of early use of endoscopy or H. pylori testing contributes to diagnostic delay.
Failure to consider NSAID use as a cause may postpone appropriate treatment.

Clinical Presentation

Signs & Symptoms

Epigastric pain worsened by meals or occurring 1-2 hours after eating is typical.
Nausea and vomiting may accompany the pain.
Weight loss can occur due to decreased oral intake.
Gastrointestinal bleeding presenting as hematemesis or melena is a common complication.
Symptoms of anemia such as fatigue and pallor may be present in chronic bleeding.

History of Present Illness

Epigastric burning or gnawing pain that worsens with food intake is typical of gastric ulcers.
Pain often occurs 1-2 hours after meals and may awaken patients at night.
Nausea, vomiting, and early satiety can accompany ulcer symptoms.
Symptoms may fluctuate with periods of remission and exacerbation over weeks to months.
Complications such as upper gastrointestinal bleeding present with hematemesis or melena.

Past Medical History

Previous H. pylori infection or gastritis increases risk of gastric ulcer.
Chronic NSAID use for arthritis or pain management is a common predisposing factor.
History of peptic ulcer disease or prior ulcer complications such as bleeding or perforation.
Coexisting conditions like chronic liver disease or renal failure may worsen ulcer risk.

Family History

Family history of peptic ulcer disease suggests genetic susceptibility to mucosal injury.
Relatives with gastric cancer may indicate shared risk factors including H. pylori infection.
No specific hereditary syndromes are strongly linked to isolated gastric ulcers.

Physical Exam Findings

Epigastric tenderness on deep palpation is common in patients with gastric ulcers.
Signs of anemia such as pallor may be present if there is chronic bleeding.
Occasionally, abdominal guarding or rigidity may indicate perforation.
Evidence of melena or occult blood may be detected on rectal exam.
No specific palpable masses are typically found unless complicated by malignancy.

Diagnostic Workup

Diagnostic Criteria

Diagnosis of gastric ulcer due to Helicobacter pylori infection requires endoscopic visualization of a gastric mucosal ulcer with biopsy. Histology or rapid urease testing of biopsy samples confirms the presence of H. pylori. Non-invasive tests such as the urea breath test or stool antigen test can also detect active infection. The ulcer is typically identified as a well-demarcated mucosal defect greater than 5 mm in diameter. Biopsy is essential to exclude malignancy and confirm infection before initiating targeted therapy.

Pathophysiology

Key Mechanisms

Chronic mucosal inflammation caused by Helicobacter pylori infection disrupts the gastric mucosal barrier.
Increased gastric acid secretion due to H. pylori-induced antral gastritis stimulates acid production by parietal cells.
Impaired mucosal defense from decreased bicarbonate secretion and mucus production leads to mucosal injury.
Direct epithelial damage by H. pylori virulence factors such as cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA).
Local ischemia and oxidative stress contribute to mucosal ulceration and delayed healing.

Involvement	Details
Organs	Stomach is the organ affected by gastric ulcers, with damage primarily to the mucosal lining causing pain and bleeding.
Organs	Duodenum may be involved in differential diagnosis as duodenal ulcers have distinct clinical features.
Tissues	Gastric mucosa is the primary site of injury in gastric ulcers due to acid and Helicobacter pylori induced inflammation.
Tissues	Submucosa may be involved in deeper ulceration leading to complications such as bleeding or perforation.
Cells	Parietal cells secrete gastric acid, whose overproduction contributes to mucosal damage in gastric ulcers.
	Gastric epithelial cells are damaged by Helicobacter pylori infection leading to ulcer formation.
	Neutrophils infiltrate the gastric mucosa as part of the inflammatory response to Helicobacter pylori.
Chemical Mediators	Gastrin stimulates acid secretion by parietal cells and is often elevated in gastric ulcer disease.
	Prostaglandins protect the gastric mucosa by promoting mucus and bicarbonate secretion and maintaining blood flow.
	Urease produced by Helicobacter pylori neutralizes gastric acid, facilitating bacterial survival and mucosal injury.

Treatments

Pharmacological Treatments

Proton Pump Inhibitors (PPIs)
- Mechanism:
  - Irreversibly inhibit the H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion.
- Side effects:
  - Headache
  - Diarrhea
  - Increased risk of Clostridioides difficile infection
- Clinical role:
  - First-line
Clarithromycin
- Mechanism:
  - Macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, targeting Helicobacter pylori.
- Side effects:
  - Gastrointestinal upset
  - Taste disturbance
  - QT prolongation
- Clinical role:
  - First-line
Amoxicillin
- Mechanism:
  - Beta-lactam antibiotic that inhibits bacterial cell wall synthesis, effective against Helicobacter pylori.
- Side effects:
  - Allergic reactions
  - Diarrhea
  - Rash
- Clinical role:
  - First-line
Metronidazole
- Mechanism:
  - Nitroimidazole antibiotic causing DNA strand breaks in anaerobic bacteria and protozoa, used against Helicobacter pylori.
- Side effects:
  - Metallic taste
  - Disulfiram-like reaction with alcohol
  - Peripheral neuropathy
- Clinical role:
  - Second-line
Bismuth Subsalicylate
- Mechanism:
  - Coats ulcers and has bactericidal effects against Helicobacter pylori, also providing mucosal protection.
- Side effects:
  - Black stools
  - Constipation
  - Bismuth toxicity with prolonged use
- Clinical role:
  - Adjunctive

Non-pharmacological Treatments

Avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce mucosal injury.
Lifestyle modifications including smoking cessation and limiting alcohol intake to promote ulcer healing.
Endoscopic evaluation for diagnosis and to assess for complications such as bleeding or perforation.

Prevention

Pharmacological Prevention

Eradication therapy with triple or quadruple regimens including proton pump inhibitors and antibiotics to eliminate H. pylori.
Proton pump inhibitors (PPIs) to reduce gastric acid secretion and promote mucosal healing.
Avoidance of NSAIDs or use of misoprostol for gastroprotection if NSAIDs are necessary.
Bismuth-containing compounds as part of quadruple therapy for resistant H. pylori.

Non-pharmacological Prevention

Avoidance of NSAIDs and other ulcerogenic medications.
Smoking cessation to reduce mucosal damage and improve healing.
Limiting alcohol intake to decrease gastric mucosal irritation.
Screening and treatment of H. pylori infection in high-risk populations.
Stress reduction and dietary modifications to avoid aggravating symptoms.

Outcome & Complications

Complications

Gastrointestinal bleeding leading to anemia or hemorrhagic shock.
Perforation causing acute peritonitis and surgical emergency.
Gastric outlet obstruction from scarring and edema.
Penetration into adjacent organs such as pancreas.
Increased risk of gastric adenocarcinoma with chronic H. pylori infection.

Short-term Sequelae	Long-term Sequelae
Acute upper GI bleeding requiring urgent stabilization and intervention. Perforation with peritonitis necessitating emergency surgery. Severe epigastric pain limiting oral intake and causing dehydration. Nausea and vomiting leading to electrolyte imbalances.	Chronic gastritis and mucosal atrophy from persistent H. pylori infection. Gastric adenocarcinoma development due to chronic inflammation and metaplasia. Pyloric stenosis causing gastric outlet obstruction. Iron deficiency anemia from ongoing occult bleeding. MALT lymphoma associated with chronic H. pylori infection.

Differential Diagnoses

Gastric Ulcer (Helicobacter pylori) versus Duodenal Ulcer

Gastric Ulcer (Helicobacter pylori)	Duodenal Ulcer
More common in older adults, usually >50 years old	Typically affects younger adults, often 30-50 years old
Ulcer located in the gastric antrum or body	Ulcer located in the proximal duodenum
Normal or decreased gastric acid secretion	Increased gastric acid secretion
Pain worsens with eating	Pain improves with eating

Gastric Ulcer (Helicobacter pylori) versus Gastric Adenocarcinoma

Gastric Ulcer (Helicobacter pylori)	Gastric Adenocarcinoma
Biopsy shows benign mucosal ulceration with Helicobacter pylori infection	Biopsy shows malignant epithelial cells with gland formation
Chronic epigastric pain with intermittent symptoms	Progressive weight loss and systemic symptoms
Discrete mucosal ulcer without mass effect	Irregular gastric wall thickening with mass lesion on endoscopy

Gastric Ulcer (Helicobacter pylori) versus NSAID-Induced Gastric Ulcer

Gastric Ulcer (Helicobacter pylori)	NSAID-Induced Gastric Ulcer
No NSAID use, but positive for Helicobacter pylori infection	History of chronic NSAID use
Ulcer with chronic active gastritis and H. pylori colonization	Ulcer with mucosal damage due to prostaglandin inhibition
Ulcer requires H. pylori eradication therapy plus acid suppression	Ulcer improves with NSAID cessation and acid suppression

Gastric Ulcer (Helicobacter pylori) versus Zollinger-Ellison Syndrome

Gastric Ulcer (Helicobacter pylori)	Zollinger-Ellison Syndrome
Normal or mildly elevated gastrin levels	Markedly elevated fasting serum gastrin levels
Single or few ulcers localized to the stomach	Multiple, refractory ulcers often in unusual locations
Ulcers heal with standard H. pylori eradication and acid suppression	Ulcers persist despite standard acid suppression

Gastric Ulcer (Helicobacter pylori) versus Gastric Lymphoma (MALT lymphoma)

Gastric Ulcer (Helicobacter pylori)	Gastric Lymphoma (MALT lymphoma)
Biopsy shows chronic active gastritis with H. pylori and no monoclonal lymphoid proliferation	Biopsy shows lymphoid infiltrate with monoclonal B cells
Usually presents with localized epigastric pain without systemic symptoms	May present with systemic B symptoms and gastric mass
Heals with H. pylori eradication and acid suppression alone	May require chemotherapy or radiotherapy; some regress with H. pylori eradication